Stephanie Cosentino, PhD, Associate Professor of Neuropsychology, and colleagues are working on developing screening tools to detect subjective cognitive decline and more advanced forms of memory loss
Richard Mayeux, MD, chair of the Department of Neurology at CUMC and colleagues are investigating a set of blood tests that may help correctly diagnose Alzheimer disease in low-resource environments
"Hispanics and individuals of African ancestry have been significantly underrepresented in research of Alzheimer’s disease, although engaging underserved minorities is critical..." says Dr. Reitz
Dr. Manly was elected to NAM for her pioneering work improving detection of cognitive impairment among racially, culturally, and socio-economically diverse adults
On Monday, the FDA approved a new drug for Alzheimer’s disease—the first in nearly two decades. Biogen’s aducanumab aims to slow the cognitive decline often associated with the disease.